<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03805308</url>
  </required_header>
  <id_info>
    <org_study_id>2018-49</org_study_id>
    <nct_id>NCT03805308</nct_id>
  </id_info>
  <brief_title>The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke</brief_title>
  <acronym>TESLA</acronym>
  <official_title>The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Health Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Health Ohio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to establish the effectiveness of IAT (versus medical
      management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with
      adaptive enrichment to better define the upper limit of infarct volume for treatment
      eligibility. Furthermore, the investigators aim to determine whether certain subgroups of
      patients with large baseline infarcts will have a greater treatment benefit. Finally, the
      investigators will assess the agreement of ASPECTS scores between site investigators, the
      core imaging lab, and automated software.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, open-label, blinded endpoint study. Patients presenting with
      symptoms of AIS who have evidence of a moderate-large infarct volume (Non-contrast CT Alberta
      Stroke Program Early CT score [NCCT ASPECTS] 2-5 in the anterior circulation will be assigned
      to either best medical management alone (including IV rtPA) or intra-arterial treatment (IAT)
      with mechanical thrombectomy added to best medical management. Each treated patient will be
      followed and assessed for 3 months after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TESLA is a pragmatic, phase III, prospective, randomized, open-label, blinded endpoint, multicenter trial. Patients with moderate-large infarcts will be assigned to either best medical management alone (including intravenous recombinant tissue-type plasminogen activator (IV rtPA)) or intra-arterial treatment (IAT) with mechanical thrombectomy added to best medical management. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the instructions for use (IFU). Patients will be enrolled at up to 25 centers over an anticipated three-year period, with an additional year for trial closeout.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The patient and the treating physician will be aware of the treatment assignment. Assessment of outcome on NIHSS and mRS will be performed by a certified rater blinded to the treatment allocation. Each site must designate one or more individual(s) to perform these blinded assessments at 24 (16-36) hours, 6 ± 1 days or discharge (whichever is earlier), 30 days ± 7 days, and 90 days ± 30 days from randomization.
Neuroimaging core lab evaluation will also be assessed in a blinded manner, except for angiographic revascularization grading which will only be performed for the intra-arterial treatment arm.
Information on treatment allocation will be stored separately from the main study database. An unblinded independent statistician will combine treatment allocation data with the clinical data in order to report to the DSMB. A second blinded statistician will be part of the steering committee.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Utility-weighted 90-day Modified Rankin Score</measure>
    <time_frame>90 days post randomization</time_frame>
    <description>Scale used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Scale ranges from 0-6 where 0 represents no symptoms and 6 represents death.
0 = No symptoms at all.
= No significant disability despite symptoms; able to carry out all usual duties and activities.
= Slight disability; unable to carry out all previous activities but able to look after own affairs without assistance.
= Moderate disability requiring some help, but able to walk without assistance.
= Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance.
= Severe disability; bedridden, incontinent, and requiring constant nursing care and attention.
= Death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Medical Management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-arterial Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-arterial Therapy</intervention_name>
    <description>Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.</description>
    <arm_group_label>Intra-arterial Therapy</arm_group_label>
    <other_name>Thrombectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 85 years of age

          2. Presenting with symptoms consistent with an acute ischemic stroke

          3. Imaging evidence of an anterior circulation occlusion of the Internal Carotid Artery
             (ICA) terminus and/or Middle Cerebral Artery Main Stem (MCA M1) segment

          4. NIHSS score &gt;6 at the time of randomization

          5. Ability to randomize within 24 hours of stroke onset

          6. Pre-stroke mRS score 0-1

          7. Ability to obtain signed informed consent

        Imaging evidence of moderate-large infarct defined as:

        1. NCCT ASPECTS 2-5

        Exclusion Criteria:

          1. Females who are pregnant, or those of child-bearing potential with positive urine or
             serum beta Human Chorionic Gonadotropin (HCG) test

          2. Known severe allergy (more than a rash) to contrast media uncontrolled by medications

          3. Refractory hypertension (defined as persistent systolic blood pressure &gt;185 mmHg or
             diastolic blood pressure &gt;110 mmHg)

          4. CT evidence of the following conditions:

               -  Midline shift or herniation

               -  Evidence of intracranial hemorrhage

               -  Mass effect with effacement of the ventricles

          5. Computed Tomography Angiography (CTA) evidence suggestive of difficult endovascular
             access per the treating interventionalist

          6. Presence of cervical ICA occlusion (e.g., related to atherosclerotic disease or
             dissection)

          7. Rapidly improving neurological status prior to randomization to NIHSS &lt;6

          8. Bilateral strokes or multiple intracranial occlusions

          9. Intracranial tumors

         10. Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant
             therapy with an International Normalized Ratio (INR) of &gt;3.0 or Partial Thromboplastin
             Time (PTT) &gt;3 times of normal

         11. Baseline platelet count &lt;30,000 per microliter (µl)

         12. Life expectancy less than 90 days prior to stroke onset

         13. Participation in another randomized clinical trial that could confound the evaluation
             of the study

         14. Any other condition (in the opinion of the site investigator) that precludes an
             endovascular procedure or poses a significant hazard to the patient if an endovascular
             procedure was performed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert J Yoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Stroke Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osama O Zaidat, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Health St. Vincent Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary S Patterson, MS</last_name>
    <phone>419-251-2335</phone>
    <email>mspatterson@mercy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesiley Trevino</last_name>
      <email>cftrevino@bhccr.com</email>
    </contact>
    <investigator>
      <last_name>Sushrut Dharmadhikari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Robles Hospital and Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasia Vechera</last_name>
    </contact>
    <investigator>
      <last_name>Asif Taqi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tenet Health Systems (Delray Medical Center, St. Mary's Medical Center, Palmetto General Hospital)</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Robbins, RN</last_name>
      <phone>561-495-3145</phone>
      <email>Gillian.Robbins@tenethealth.com</email>
    </contact>
    <investigator>
      <last_name>Nils Mueller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System - South Broward Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erum Usman</last_name>
      <email>EUsman@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Brijesh Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Scott</last_name>
      <email>descott@health.usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Konrad Bach</last_name>
      <email>kbach@usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maxim Mokin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellstar Health System, Inc.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca McConnell, BSN</last_name>
      <phone>770-434-6959</phone>
      <email>Rebecca.McConnell@wellstar.org</email>
    </contact>
    <contact_backup>
      <last_name>Martha Kelly</last_name>
      <phone>4707934064</phone>
      <email>Martha.Kelly@wellstar.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rishi Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heena Olalde, RN, MSN</last_name>
      <phone>319-356-8326</phone>
      <email>heena-olalde@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Santiago Ortega Gutierrez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univresity of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gay</last_name>
      <email>jgay@ubns.com</email>
    </contact>
    <investigator>
      <last_name>Hussain Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Feinstein Institute for Medical Research, Northwell</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prathusan Subramaniam, BS</last_name>
      <phone>516-881-7012</phone>
      <email>PSubramaniam@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Wann, BS</last_name>
      <email>lwann1@northwell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Health St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Thomas</last_name>
    </contact>
    <investigator>
      <last_name>Osama O Zaidat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Launchbury</last_name>
      <phone>503-418-1722</phone>
      <email>nadeauk@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Hormozd Bozorgchami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University of Health Sciences</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Villalobos</last_name>
    </contact>
    <contact_backup>
      <last_name>Susana.Villalobos@ttuhsc.edu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Alberto Maud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor S Lopez</last_name>
      <email>Victor.S.LopezRivera@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sunil Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Stroke Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Vo, MS</last_name>
      <phone>469-401-2471</phone>
      <email>Peggy.Vo@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Albert J Yoo, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Gilman, RN</last_name>
      <phone>804-828-0374</phone>
      <email>charlotte.gilman@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Dennis J Rivet II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Health Ohio</investigator_affiliation>
    <investigator_full_name>Dr. Osama O. Zaidat</investigator_full_name>
    <investigator_title>Neuroscience and Stroke Medical Director</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All shared data will be aggregate.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

